Werbung
Werbung

TELO

TELO logo

Telomir Pharmaceuticals, Inc. Common Stock

1.43
USD
Gesponsert
-0.04
-2.73%
08. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

1.44

+0.01
+0.70%

TELO Ergebnisberichte

Positives Überraschungsverhältnis

TELO übertreffen die 2 der letzten 4Schätzungen.

50%

Nächster Bericht

Datum des nächsten Berichts
02. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.07
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
+133.33%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
-22.22%

Telomir Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 10. Nov. 2025, TELO reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.07 USD, resulting in a 57.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an increase of 133.33% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26. Dez. 2025 For Q4 25
Estimate
-$0.49
Aktuell
-
Überraschung
-
FAQ
For Q3 2025, Telomir Pharmaceuticals, Inc. Common Stock reported EPS of -$0.03, beating estimates by 57.98%, and revenue of $0.00, 0% as expectations.
The stock price moved up 3.65%, changed from $1.37 before the earnings release to $1.42 the day after.
The next earning report is scheduled for 02. Feb. 2026.
Based on 3 analysts, Telomir Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung